Lipoprotein(a) Testing and the Executive Physical: The Genetic Cardiovascular Risk Most Miami Physicals Still Miss

Lipoprotein(a) Testing and the Executive Physical: The Genetic Cardiovascular Risk Most Miami Physicals Still Miss

Lipoprotein(a) — or Lp(a) — is the strongest single genetic risk factor for atherosclerotic cardiovascular disease, and it is now recommended that every adult have their Lp(a) measured at least once in their lifetime. Yet most standard executive physicals in Miami still do not include it. At PURE Executive Health & Wellness in Coral Gables, Lp(a) testing is a core component of our concierge executive physical, integrated with advanced cardiovascular imaging, biological age testing, and a physician-led longevity strategy.

The genetic cardiovascular risk factors standard medicine still ignores

Roughly one in five adults carries an elevated Lp(a) level that is causing measurable atherosclerotic damage right now — in many cases, for decades before any standard cholesterol panel suggests there is a problem. According to PubMed, a 2024 review in the American Journal of Preventive Cardiology describes Lp(a) as “the most prevalent inherited dyslipidemia and strongest genetic ASCVD risk factor” — a risk that persists even when LDL-C is at guideline-recommended targets and a patient is doing everything right on lifestyle (DOI: 10.1016/j.ajpc.2024.100651).

For executives in the city of Coral Gables, Brickell, Fisher Island, and Indian Creek who manage portfolios, companies, and complex global lives with precision, an unmeasured Lp(a) value is a strategic blind spot. You cannot manage what you have never measured. And in this case, what you have not measured is causally tied to your risk of heart attack, stroke, and aortic stenosis.

That is precisely why PURE’s executive physical in Miami was redesigned around precision diagnostics that go several layers deeper than the standard annual exam. Lipoprotein(a) measurement is one of those layers — and for many of the executives we serve, it is the single piece of information that has most changed their long-term cardiovascular trajectory.

What is Lipoprotein(a), and why is it different from cholesterol?

Lipoprotein(a), pronounced “L-P-little-a,” is a type of lipoprotein, a specialized particle made of fats and proteins that carries hydrophobic lipids through the bloodstream, and it is structurally similar to LDL cholesterol but with an additional protein attached called apolipoprotein(a).

< div class=”sidebar”> < strong>What is a Lipoprotein?< /strong>< br> Lipoproteins are specialized particles composed of fats and proteins. They transport hydrophobic lipids through the bloodstream. Each lipoprotein has a core of fat molecules and an outer shell of phospholipids and proteins. Lipoproteins are classified by their density, which is determined by the protein-to-fat ratio. Chylomicrons transport dietary lipids from the intestines to body tissues. Very Low-Density Lipoproteins carry endogenous fats from the liver to the body. Low-Density Lipoproteins deliver cholesterol to peripheral cells and organs. High-Density Lipoproteins perform reverse cholesterol transport. Some lipoproteins can also bind and neutralize bacterial toxins or viruses. < /div>

Lipoproteins have a core of fat molecules with an outer shell of phospholipids and proteins, and they are classified by density based on the protein-to-fat ratio. Lp(a) is stickier than other LDL particles, so high levels of Low-Density Lipoproteins can drive plaque buildup in arteries, raise the risk of blood clots, and contribute directly to calcification of the aortic valve.

Your Lp(a) level is roughly 80 to 90 percent genetically determined, so what you eat has little effect on Lp(a) itself. It is established early in life because genes in cells strongly influence production, remains essentially stable across decades, and is largely unaffected by diet, exercise, or the statins that effectively lower LDL-C. According to PubMed, the 2024 focused update of the National Lipid Association Scientific Statement on Lp(a) confirmed that there is now sufficient evidence to recommend measuring Lp(a) at least once in every adult for cardiovascular risk stratification, with elevated risk defined at ≥50 mg/dL (or ≥125 nmol/L) and high lipoprotein(a) acting as an independent risk factor; these particles also help transport cholesterol needed to build cell membranes and hormones (DOI: 10.1016/j.jacl.2024.03.001).

Despite that guidance, measurement rates remain low in conventional practice. A 2025 clinical review in Clinical Biochemistry emphasized that elevated Lp(a) is widely prevalent and that several cardiovascular societies now recommend universal one-time screening — yet the gap between guideline and practice continues to leave high-risk individuals identified only after a cardiovascular event (DOI: 10.1016/j.clinbiochem.2025.110929).

The 30-year evidence: why Lp(a) belongs in every executive health assessment in Miami

The case for measuring Lp(a) in an executive physical is no longer based on extrapolation. According to PubMed, a landmark 2024 study published in The New England Journal of Medicine followed 27,939 initially healthy women for 30 years and demonstrated that baseline levels of high-sensitivity CRP, LDL-C, and Lp(a) each independently predicted major cardiovascular events three decades later. Compared with the lowest quintile, women in the highest Lp(a) quintile had an adjusted 33 percent higher long-term risk for cardiovascular events — independent of LDL-C and inflammation (DOI: 10.1056/NEJMoa2405182). Elevated Lp(a) also helps explain lifetime heart disease risk even when traditional 10-year estimates look reassuring.

That study reframes how cardiovascular risk should be assessed for high-performing adults in their forties and fifties. Traditional 10-year Framingham-style risk calculators systematically underestimate lifetime risk in this population. A 30-year horizon is the right frame for an executive who reasonably expects to be running a business, sitting on boards, or active with grandchildren well into their eighties. Lp(a) is part of that 30-year picture in a way no other single biomarker is.

According to PubMed, a 2025 analysis from the Multi-Ethnic Study of Atherosclerosis (MESA) — published in the European Journal of Preventive Cardiology — confirmed that approximately 20 percent of the cohort had Lp(a) at or above 50 mg/dL, and that absolute cardiovascular event rates were higher in this group across every category of lifestyle adherence. Importantly, optimal lifestyle measured by the American Heart Association’s Life’s Simple 7 score still reduced risk substantially in individuals with elevated Lp(a), confirming that lifestyle remains powerful — but does not erase the underlying genetic risk (DOI: 10.1093/eurjpc/zwae382).

What PURE’s executive physical blood test in Coral Gables actually measures

Lp(a) Measurement

The PURE executive health assessment was designed by board-certified physicians around the principle that a luxury executive physical in South Florida should reflect the current state of cardiovascular science — not a 1990s checklist.

• A one-time lipoprotein(a) measurement using a validated, apolipoprotein(a) isoform-independent assay, reported in molar units (nmol/L) per current expert consensus on standardization.

Additional Cardiovascular Markers

• Apolipoprotein B (apoB) particle number measurement, which more accurately quantifies atherogenic particle burden than LDL-C alone.
• High-sensitivity C-reactive protein (hs-CRP), as supported by the 30-year NEJM data above.

Advanced Imaging and Biomarkers

• A coronary artery calcium (CAC) score, where clinically indicated, to directly visualize and quantify subclinical atherosclerosis.
• Full-body MRI
• Advanced cardiovascular imaging
• VO2 max measurement via direct gas exchange
• DEXA body composition with visceral fat quantification
• Biological age scoring via second-generation epigenetic clocks
• APOE genotyping
• Hormone optimization assessment

Personalized Interpretation and Longevity Blueprint

Each result is interpreted in clinical context by your physician — not flagged in a portal and forgotten. For PURE members across concierge medicine Coral Gables, Brickell, Fisher Island, and Indian Creek, the deliverable is a written longevity blueprint that integrates Lp(a) status with everything else we measure into a single, prioritized clinical strategy, while also weighing symptoms and family history alongside those biomarker findings.

What an elevated Lp(a) actually changes about your care

The clinical implications of an elevated Lp(a) reading are concrete. According to PubMed, current NLA guidance recommends that individuals with elevated Lp(a) receive earlier and more intensive cardiovascular risk factor management — including more aggressive LDL-C lowering, blood pressure optimization, lifestyle intensification, and consideration of additional imaging such as coronary artery calcium scoring (DOI: 10.1016/j.jacl.2024.03.001). A recent alcohol drink can raise triglycerides and may affect how a lipid-related blood test is interpreted.

Cascade screening of first-degree relatives is also recommended, because Lp(a) is inherited. For families in Coral Gables, Brickell, and Pinecrest where multiple generations may be served by PURE, identifying elevated Lp(a) in one adult opens a logical conversation about testing adult children, siblings, and parents — well in advance of any clinical event. Levels can also shift while pregnant, so results may need different interpretation or repeat testing postpartum.

Currently, no medication is FDA-approved specifically to lower Lp(a) levels, but lipoprotein apheresis is the FDA-approved therapy used in selected patients with high Lp and established cardiovascular risk. However, multiple targeted therapies are in late-stage clinical development. According to PubMed, a 2025 review in Pharmaceuticals summarizes the active investigational pipeline: pelacarsen (an antisense oligonucleotide), and olpasiran, zerlasiran, and lepodisiran (small interfering RNA agents), along with muvalaplin (an oral small molecule). Phase 3 cardiovascular outcome trials are ongoing for several of these agents (DOI: 10.3390/ph18050753). Researchers are still studying how best to use Lp(a) testing and targeted therapies over time. Talk with your provider or health care professional about your test results, since your clinician may suggest more intensive management of other risk factors, including diabetes, based on your results.

For executives identified today as having elevated Lp(a), the practical implication is meaningful: when these therapies receive regulatory approval — likely within the next several years — the patients who will benefit first are those whose Lp(a) status is already documented, whose cardiovascular risk has already been mapped, and whose physician already knows them. Measuring Lp(a) now is, in part, an investment in being ready when targeted treatment becomes available.

Why this matters more in a concierge medicine model

An elevated Lp(a) reading is not actionable in fifteen minutes. It requires interpretation against the rest of your cardiovascular picture, a conversation about family history, a coordinated plan with imaging, and follow-up that does not depend on you remembering to chase down a portal message. That kind of integrated care is structurally difficult in a conventional practice that may carry 2,000 to 3,000 patients per physician.

This model is designed to help protect long-term cardiovascular health through earlier screening and sustained follow-up.

PURE’s concierge medicine Coral Gables model is built around a deliberately limited patient panel of fewer than 200 per physician. That ratio is the foundation that makes precision interpretation of biomarkers like Lp(a) possible — unhurried appointments, direct physician access, personalized protocols, and continuity across years rather than visits. For executive families on Fisher Island, in Indian Creek, in Brickell, and throughout Coral Gables, that depth of physician relationship is the operational difference between data collected and data acted on.

Frequently asked questions

What is Lipoprotein(a) and why should I be tested for it?

Lipoprotein(a), or Lp(a), is a genetically determined cholesterol-like particle that is causally linked to atherosclerotic cardiovascular disease and aortic valve stenosis. According to PubMed, current guidance from the National Lipid Association recommends that every adult have Lp(a) measured at least once in their lifetime for cardiovascular risk stratification, because approximately one in five adults carries an elevated level that confers substantially higher long-term cardiovascular risk independent of LDL cholesterol (DOI: 10.1016/j.jacl.2024.03.001).

Is Lp(a) testing included in a standard annual physical in Miami?

In most conventional practices, no. Lp(a) is not part of routine cholesterol screening, and this blood test is rarely ordered outside of specialty preventive cardiology and concierge longevity medicine programs. PURE’s executive physical in Coral Gables includes Lp(a) testing as a core component of every comprehensive assessment.

What Lp(a) level is considered high?

According to the 2024 National Lipid Association focused update, an Lp(a) level below 75 nmol/L (about 30 mg/dL) is considered low risk, 75 to 125 nmol/L (30 to 50 mg/dL) is intermediate risk, and ≥125 nmol/L (≥50 mg/dL) is considered high risk for atherosclerotic cardiovascular disease (DOI: 10.1016/j.jacl.2024.03.001). Note that a high result should be interpreted by a clinician in the context of the patient’s overall risk rather than in isolation. A high level should still be interpreted in the context of the patient’s overall risk, even if other cholesterol levels appear normal.

Can I lower my Lp(a) with diet, exercise, or statins?

Lp(a) is roughly 80 to 90 percent genetically determined, levels usually remain stable throughout life, and it is largely unaffected by lifestyle changes or standard statin therapy. However, lifestyle remains highly effective at reducing overall cardiovascular event rates even in individuals with elevated Lp(a), and aggressive optimization of LDL-C, blood pressure, and other modifiable risk factors is the current standard of care while targeted Lp(a)-lowering therapies complete late-stage clinical trials.

If my Lp(a) is high, what does PURE actually do about it?

If your Lp(a) is high, PURE initiates a coordinated clinical plan that includes:

• Intensified LDL-C and apoB targets
• Blood pressure optimization
• Evaluation for coronary artery calcium imaging
• Cascade screening of first-degree relatives where appropriate
• Structured monitoring against the same biomarker stack used at baseline
• Ongoing updates about emerging Lp(a)-lowering therapies as they progress through trials and become available

How do I schedule an executive physical with Lp(a) testing in Miami?

PURE Executive Health & Wellness is located at 4100 Salzedo Street, Suite 4, Coral Gables, FL, serving executive families across Miami Beach, Brickell, Coconut Grove, Coral Gables, Key Biscayne, Fisher Island, Indian Creek, Pinecrest, and South Miami. To book an appointment, schedule directly with our health care provider team.

The strategic takeaway

If you have built a life that demands precision in every other domain — your portfolio, your business, your travel logistics — your cardiovascular risk assessment deserves the same standard. Lp(a) is the single most important inherited cardiovascular risk factor in adult medicine, and the one most likely to be missing from your last physical. Measuring it once is straightforward. Interpreting it correctly, integrating it with the rest of your biomarker profile, and acting on it over decades is what PURE’s concierge longevity medicine program in Coral Gables was built to do.

To explore PURE’s executive physical and concierge longevity medicine program in Miami, deepen your understanding of Lp(a) risk, or schedule a confidential consultation, contact our physician team. Related reading: Concierge Medicine in Coral Gables, Concierge Medicine in Brickell, Concierge Medicine on Fisher Island, and Concierge Medicine in Indian Creek.

Practice: PURE Executive Health & Wellness

Specialty: Concierge longevity medicine, executive physicals, precision diagnostics

Location: 4100 Salzedo Street, Suite 4, Coral Gables, FL 33146

Area served: Miami Beach, Brickell, Coconut Grove, Coral Gables, Key Biscayne, Fisher Island, Indian Creek, Pinecrest, South Miami

Lead service in this article: Lipoprotein(a) testing as part of comprehensive executive health assessment

Phone consultation: Schedule via purehealthmiami.com